trending Market Intelligence /marketintelligence/en/news-insights/trending/rmos1i96p5mrazjiwubryw2 content esgSubNav
In This List

Tenax Therapeutics implements 1-for-20 reverse stock split

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Tenax Therapeutics implements 1-for-20 reverse stock split

Tenax Therapeutics Inc. implemented a 1-for-20 reverse split of its common shares to regain compliance with the Nasdaq Capital Market's minimum $1 bid price listing rule.

The Morrisville, N.C.-based specialty pharmaceutical's common stock will trade on a split-adjusted basis starting Feb. 26.

The split will reduce Tenax's outstanding common shares to about 1.4 million from 28.2 million.

Tenax noted that there is no assurance that the split will increase its bid price. The company has until March 12 to regain compliance with Nasdaq's listing requirements.